ArticleXenobiotica; the fate of foreign compounds in biological systems2021
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens.
Article in Xenobiotica; the fate of foreign compounds in biological systems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.Frontiers in medicine · 2021Pooled it
- Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis.Arthritis care & research · 2025Trial
- The Efficacy of Colchicine as an Adjunct Therapy in Non-hospitalized COVID-19 Patients: A Randomized Placebo-Controlled Trial.Recent advances in anti-infective drug discovery · 2024Trial
- Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID).Journal of general internal medicine · 2022Trial
- Article
- Assessing the Impact of Colchicine on Pulmonary Fibrosis Using Imaging in Patients With Moderate-to-Severe COVID-19 Pneumonia.Canadian respiratory journal · 2026Article
- The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing.Clinical pharmacokinetics · 2025Article
- Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model.Rheumatology and therapy · 2025Article
- Colchicine-The Divine Medicine against COVID-19.Journal of personalized medicine · 2024Review
- Article
- Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients.Immunity, inflammation and disease · 2024Article
- Colchicine's Role in Cardiovascular Disease Management.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Colchicine: the good, the bad, the ugly and how to minimize the risks.Rheumatology (Oxford, England) · 2024Article
- Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease.RMD open · 2024Article
- Review
- Strategies for the Management of Spike Protein-Related Pathology.Microorganisms · 2023Review
- Determination of Colchicine in Pharmaceutical Formulations, Traditional Extracts, and Ultrasonication-Based Extracts ofPlants (Basel, Switzerland) · 2022Article
- Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.Antibiotics (Basel, Switzerland) · 2022Article
- Review
- Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease.The American journal of medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colchicine is widely investigated for cardioprotection of COVID-19 patients since it can prevent the phenomenon of 'cytokine storm' and may reduce the complications arising from COVID-19. Despite the potentially beneficial effects of colchicine, there is no consensus on the appropriate dosage regimen and numerous schemes are currently used.In this study, simulations were performed to identify the ability of dosage regimens to attain plasma levels in CVOID-19 patients, known to be generally safe and efficacious. Since renal and hepatic impairment, as well as, drug-drug interactions have been identified to be the most significant factors increasing colchicine toxicity, the impact of these interactions was assessed in the simulations.Some dosage regimens lead to high colchicine concentrations, while others result in sub-therapeutic levels. Additional dosage schemes were proposed in this study aiming to be applied in patients with clearance insufficiency. Colchicine administration of 0.5 mg twice daily, can be considered safe and effective. In cases of clearance impairment, doses as low as 0.25 mg thrice or twice daily should be applied.Colchicine is a narrow therapeutic index drug and dosage regimens tailored to patients' needs should be designed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.